商品名：Adequan Canine, Adequan IA, and Adequan IM
Polysulfated glycosaminoglycan (PSGAG) provides large-molecular-weight compounds similar to normal constituents of healthy joints. It is chondroprotective and inhibits enzymes that may degrade articular cartilage, such as metalloproteinase. It may help to upregulate glycosaminoglycan and collagen synthesis and decrease inflammatory mediators (e.g., PGE2).
PSGAG is injected in dogs and horses to treat or prevent degenerative joint disease. Intra-articular injections have been effective, but intramuscular doses may be too low to be effective in some animals.
劑量數字暫停提供：VetPro 的劑量改依 DRUGAPI 藥物資料庫對外的內容，DRUGAPI 目前不提供可直接計算的劑量。下方列出 DRUGAPI 的審查結論與劑量審查引用的來源；計算機可手動輸入劑量換算。
PSGAG 具多個不可互換注射／外用產品且有 active glass-fiber recall；exact product、NADA/device、物種、route、濃度、瓶型、批號、召回、適應症、出血／無菌與法域 gate 未齊前全面 fail closed。
DRUGAPI 劑量審查引用的獸醫官方標示（各標示只適用於其產品、物種與法域，不可互換）
依出現頻率分組；嚴重副作用獨立列出，臨床上需立即辨識。